Combination therapy for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new drug combination (tunlametinib, AG, and cetuximab) as the first treatment for advanced pancreatic cancer. It may help people who have not had prior therapy and whose cancer has not spread to the brain or caused other serious health issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced pancreatic cancer confirmed by a biopsy.
- You must not have received any previous cancer treatment for this disease.
- You must be able to take pills by mouth.
- You must have at least one tumor that can be measured on a scan.
- Your general health must be good enough to carry out daily activities (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This trial tests a combination of two targeted drugs (Tunlametinib and an anti-EGFR antibody) in people with advanced pancreatic or colorectal cancer that has a RAS mutation and has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial tests a combination of three drugs—capecitabine (a chemotherapy pill), camrelizumab (an immunotherapy), and apatinib (a targeted therapy)—for people with advanced pancreatic cancer whose previous treatment stopped working or who cannot tolerate standard chemotherapy.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
Hear when a new Pancreatic Cancer Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.